Abstract
Many natural and synthetic compounds bind to tubulin, an ubiquitous globular protein that provides the building blocks for the cellular microtubule network that controls chromosome segregation during mitosis, vesicle movements, intracellular transport of organelles, ciliar and flagellar movement, and maintenance of cell shape. Since the isolation of the antimitotic marine natural product curacin A in 1994, synthetic work on this colchicine-site binding agent has been intense, but only recently have synthetic derivatives been identified that match its potency for tubulin polymerization inhibition and its high level of growth inhibition in cancer cell lines. In addition to several total synthesis efforts, combinatorial libraries were constructed using solution phase and fluorous scavenging approaches. Low watersolubility and lack of chemical stability represent strong detriments for the clinical development of curacin A, but synthetic analogs with improved bioavailability might ultimately probe the paradigm for anticancer efficacy of colchicinesite tubulin binding agents.
Keywords: curacin a, colchicine, tubulin, antimitotic agents, bioisosteres, anticancer activity, sar, natural products
Current Pharmaceutical Design
Title: Chemistry and Biology of Curacin A
Volume: 10 Issue: 12
Author(s): Peter Wipf, Jonathan T. Reeves and Billy W. Day
Affiliation:
Keywords: curacin a, colchicine, tubulin, antimitotic agents, bioisosteres, anticancer activity, sar, natural products
Abstract: Many natural and synthetic compounds bind to tubulin, an ubiquitous globular protein that provides the building blocks for the cellular microtubule network that controls chromosome segregation during mitosis, vesicle movements, intracellular transport of organelles, ciliar and flagellar movement, and maintenance of cell shape. Since the isolation of the antimitotic marine natural product curacin A in 1994, synthetic work on this colchicine-site binding agent has been intense, but only recently have synthetic derivatives been identified that match its potency for tubulin polymerization inhibition and its high level of growth inhibition in cancer cell lines. In addition to several total synthesis efforts, combinatorial libraries were constructed using solution phase and fluorous scavenging approaches. Low watersolubility and lack of chemical stability represent strong detriments for the clinical development of curacin A, but synthetic analogs with improved bioavailability might ultimately probe the paradigm for anticancer efficacy of colchicinesite tubulin binding agents.
Export Options
About this article
Cite this article as:
Wipf Peter, Reeves T. Jonathan and Day W. Billy, Chemistry and Biology of Curacin A, Current Pharmaceutical Design 2004; 10 (12) . https://dx.doi.org/10.2174/1381612043384853
DOI https://dx.doi.org/10.2174/1381612043384853 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strategic Developments & Future Perspective on Gene Therapy for Breast Cancer: Role of mTOR and Brk/ PTK6 as Molecular Targets
Current Gene Therapy Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science Sympathetic Nervous System Dysfunction in Multiple Sclerosis, Linking Neurodegeneration to a Reduced Response to Therapy
Current Pharmaceutical Design What Have We Learned from the Novel Human Cytochromes P450 Hidden in the Databases?
Current Genomics The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Inhibition of Testosterone Aromatization by the Indole-3-carbinol Derivative CTet in CYP19A1-overexpressing MCF-7 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting the Hedgehog Signaling Pathway with Small Molecules
Anti-Cancer Agents in Medicinal Chemistry Biodegradable Polymeric Nanoparticles as the Delivery Carrier for Drug
Current Drug Delivery Targeting Hsp90 in Non-Cancerous Maladies
Current Topics in Medicinal Chemistry Dietary Polyphenols for Prostate Cancer Therapy
Current Bioactive Compounds Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science Software Analysis of Two-Dimensional Electrophoretic Gels in Proteomic Experiments
Current Bioinformatics NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design A Role for Tumor Suppressor Protein p53 in the Fidelity of DNA Synthesis and Resistance Towards Nucleoside Analogs
Current Cancer Therapy Reviews Contribution of Efflux Pump Activity to the Delivery of Pulmonary Therapeutics
Current Drug Metabolism Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Biologically Active Agents
Current Medicinal Chemistry Effects of Estrogens on Atherogenesis
Current Vascular Pharmacology Conserved Regions can Predict Protein Binding Regions
Current Proteomics Molecular Modeling Applied to Anti-Cancer Drug Development
Anti-Cancer Agents in Medicinal Chemistry